Trial · NCT03260023
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phase I - TG4001 5x10e6 Pfu + Avelumab | 3 | |
| Overall Study | STARTED | Phase I - TG4001 5x10e7 Pfu + Avelumab | 6 | |
| Overall Study | STARTED | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | 34 | |
| Overall Study | STARTED | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | 46 | |
| Overall Study | STARTED | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | 44 | |
| Overall Study | STARTED | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | 5 | |
| Overall Study | STARTED | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab | 5 | |
| Overall Study | COMPLETED | Phase I - TG4001 5x10e6 Pfu + Avelumab | 3 | |
| Overall Study | COMPLETED | Phase I - TG4001 5x10e7 Pfu + Avelumab | 5 | |
| Overall Study | COMPLETED | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | 25 | |
| Overall Study | COMPLETED | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | 35 | |
| Overall Study | COMPLETED | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | 33 | |
| Overall Study | COMPLETED | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | 4 | |
| Overall Study | COMPLETED | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab | 3 | |
| Overall Study | NOT COMPLETED | Phase I - TG4001 5x10e6 Pfu + Avelumab | 0 | |
| Overall Study | NOT COMPLETED | Phase I - TG4001 5x10e7 Pfu + Avelumab | 1 | |
| Overall Study | NOT COMPLETED | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | 9 | |
| Overall Study | NOT COMPLETED | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | 11 | |
| Overall Study | NOT COMPLETED | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | 11 | |
| Overall Study | NOT COMPLETED | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03260023/flow